Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corp director Christopher R. Reidy increased his direct holdings through routine equity compensation events. On April 16, 2026, he acquired 334 shares of Encompass Health Common Stock at a weighted average of $106.48 per share as a grant or award. On April 15, 2026, he also acquired 19 shares at $0.00 per share through a directors’ deferred stock investment plan and dividend reinvestment tied to a $0.19 per share dividend and a $105.24 closing price. Following these transactions, he directly holds 15,803 shares of Encompass Health Common Stock.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an automatic grant of 39 restricted stock units (RSUs) tied to a dividend payment. These RSUs were credited on April 15, 2026 in connection with Encompass Health’s common stock dividend of $0.19 per share.
The RSU credit was calculated based on the number of RSUs already in the director’s account, the per share dividend, and the closing stock price of $105.24 on the dividend payment date. After this award, Schlichting directly holds 21,298 shares of Encompass Health common stock. This is a routine, non-cash compensation-related accrual rather than an open-market stock purchase or sale.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received 27 restricted stock units (RSUs) as a grant tied to a dividend payment. These RSUs were credited on April 15, 2026, when the company paid a $0.19 per share dividend and the stock closed at $105.24. After this award, Williams directly holds a total of 15,196 shares/RSUs of Encompass Health common stock. The transaction reflects a compensation-related RSU credit rather than an open-market stock purchase.
Encompass Health Corporation is asking stockholders to vote at its 2026 annual meeting, which will be held virtually on May 7, 2026 at 11:00 a.m. central time. Holders of common stock as of March 9, 2026 may participate and vote online using a 16-digit control number.
Stockholders are being asked to elect 10 directors for one-year terms, ratify PricewaterhouseCoopers LLP as independent auditor, and approve on an advisory basis executive compensation. The board highlights a long-running pay-for-performance program, strong governance practices, and prior say-on-pay support above 93%, including 97.6% approval in 2025.
Encompass Health Corp ownership disclosure: The Vanguard Group filed an amendment to its Schedule 13G stating it beneficially owns 0 shares of Encompass Health Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries/divisions to report separately.
Encompass Health Corporation entered a new credit agreement on March 9, 2026, establishing a $1 billion revolving credit facility with a maturity of March 9, 2031. The facility includes a $260 million letter of credit subfacility and a swingline loan sublimit increased to $40 million.
The company used $250.0 million of borrowings and $53.6 million of letters of credit under the new facility to repay and retire all remaining obligations under its prior 2022 credit agreement, which was terminated along with its related collateral and guarantee agreement.
The new agreement keeps terms substantially similar but lowers the undrawn commitment fee by 5 basis points, eliminates a 0.10% Term SOFR interest adjustment, relaxes certain investment, debt, lien, and restricted payment limits, and adds an accordion feature allowing additional term loans or increased revolving commitments, subject to leverage and coverage covenants.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported an open-market sale and a charitable gift of company stock. On March 9, 2026, he sold 11,937 shares of Encompass Health common stock at $107 per share, then donated 3,000 shares as a bona fide gift to a donor advised fund administered by Schwab. After these transactions, Fay directly holds 86,325 shares of Encompass Health common stock, indicating he retains a substantial equity stake in the company.
Encompass Health Corp Chief Accounting Officer handles tax withholding via share disposition
Encompass Health Corp executive Andrew L. Price reported a tax-withholding disposition of 307 shares of Encompass Health common stock on this Form 4. The shares, valued at $107.88 each, were withheld or surrendered to cover tax obligations from vesting restricted stock, not sold in an open‑market trade.
After this transaction, Price directly holds 74,694 shares of Encompass Health common stock.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported a small share disposition related to tax withholding. On the transaction date, 280 shares of Encompass Health common stock were withheld at $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, Fay directly owned 101,262 shares of Encompass Health common stock.